ARS Pharmaceuticals
SPRY
SPRY
113 hedge funds and large institutions have $612M invested in ARS Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
13% more funds holding
Funds holding: 100 → 113 (+13)
6.2% less ownership
Funds ownership: 68.26% → 62.06% (-6.2%)
Holders
113
Holding in Top 10
3
Calls
$6.42M
Puts
$1.02M
Top Buyers
| 1 | +$14.3M | |
| 2 | +$10.5M | |
| 3 | +$8.86M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.97M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$4.06M |
Top Sellers
| 1 | -$21.9M | |
| 2 | -$11.7M | |
| 3 | -$11M | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.75M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$8.54M |